Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
A diminution of quality of life is often reported by patients after coronary artery bypass
graft (CABG) surgery. A part of this diminution could be explain by postoperative left
ventricular (LV) dysfunction.
Exenatide (Byetta®) is an incretin mimetic, characterized by an anti-hyperglycemic effect
that depends on the blood glucose level. Recent data have suggested that exenatide could
improve LV function by an inotropic effect in patients suffering from cardiogenic shock or
from congestive heart failure. Moreover, patients suffering from congestive heart failure
reported a better quality of life when they were treated with exenatide compared to placebo.
The investigators hypothesize that perioperative exenatide infusion could improve
postoperative quality of life in CABG surgery patients.